|
1
|
Tashiro K, Tada H, Heilker R, et al:
Signal sequence trap: a cloning strategy for secreted proteins and
type I membrane proteins. Science. 261:600–603. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murphy PM, Baggiolini M, Charo IF, et al:
International union of pharmacology. XXII Nomenclature for
chemokine receptors. Pharmacol Rev. 52:145–176. 2000.PubMed/NCBI
|
|
3
|
Balabanian K, Lagane B, Infantino S, et
al: The chemokine SDF-1/CXCL12 binds to and signals through the
orphan receptor RDC1 in T lymphocytes. J Biol Chem.
280:35760–35766. 2005. View Article : Google Scholar
|
|
4
|
Ratajczak MZ, Zuba-Surma E, Kucia M, et
al: The pleiotropic effects of the SDF-1-CXCR4 axis in
organogenesis, regeneration and tumorigenesis. Leukemia.
20:1915–1924. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burns JM, Summers BC, Wang Y, et al: A
novel chemokine receptor for SDF-1 and I-TAC involved in cell
survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kryczek I, Wei S, Keller E, Liu R and Zou
W: Stroma-derived factor (SDF-1/CXCL12) and human tumor
pathogenesis. Am J Physiol Cell Physiol. 292:C987–C995. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scotton CJ, Wilson JL, Milliken D, Stamp G
and Balkwill FR: Epithelial cancer cell migration: a role for
chemokine receptors? Cancer Res. 61:4961–4965. 2001.PubMed/NCBI
|
|
8
|
Scotton CJ, Wilson JL, Scott K, et al:
Multiple actions of the chemokine CXCL12 on epithelial tumor cells
in human ovarian cancer. Cancer Res. 62:5930–5938. 2002.PubMed/NCBI
|
|
9
|
Feuerer M, Beckhove P, Bai L, et al:
Therapy of human tumors in NOD/SCID mice with patient-derived
reactivated memory T cells from bone marrow. Nat Med. 7:452–458.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou W, Machelon V, Coulomb-L’Hermin A, et
al: Stromal-derived factor-1 in human tumors recruits and alters
the function of plasmacytoid precursor dendritic cells. Nat Med.
7:1339–1346. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kryczek I, Gryboś M, Dlubek D, Klimczak A,
Rabczyński J and Lange A: Accumulation of CD45RO(+) cells in
peritoneal carcinomatous fluid favours survival of ovarian
carcinoma patients. Cancer Immunol Immunother. 51:513–519.
2002.
|
|
12
|
Jaszczyñska-Nowinka K and Markowska A: New
cytokine: stromal derived factor-1. Eur J Gynaecol Oncol.
30:124–127. 2009.PubMed/NCBI
|
|
13
|
Broxmeyer HE, Orschell CM, Clapp DW, et
al: Rapid mobilization of murine and human hematopoietic stem and
progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med.
201:1307–1318. 2005. View Article : Google Scholar
|
|
14
|
Zhang T, Somasundaram R, Berencsi K, et
al: CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha)
and CXCR4-dependent migration of CTLs toward melanoma cells in
organotypic culture. J Immunol. 174:5856–5863. 2005. View Article : Google Scholar
|
|
15
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang YP, Wu XH, Shi B, Wu WX and Yin GR:
Expression of chemokine CXCL12 and its receptor CXCR4 in human
epithelial ovarian cancer: an independent prognostic factor for
tumor progression. Gynecol Oncol. 103:226–233. 2006. View Article : Google Scholar
|
|
17
|
Furuya M, Suyama T, Usui H, et al:
Up-regulation of CXC chemokines and their receptors: implications
for proinflammatory microenvironments of ovarian carcinomas and
endometriosis. Hum Pathol. 38:1676–1687. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pils D, Pinter A, Reibenwein J, et al: In
ovarian cancer the prognostic influence of HER2/neu is not
dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer.
96:485–491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rucinski M, Andreis PG, Ziolkowska A,
Nussdorfer GG and Malendowicz LK: Differential expression and
function of beacon in the rat adrenal cortex and medulla. Int J Mol
Med. 16:35–40. 2005.PubMed/NCBI
|
|
20
|
Rucinski M, Zok A, Guidolin D, De Caro R
and Malendowicz LK: Expression of precerebellins in cultured rat
calvaria osteoblast-like cells. Int J Mol Med. 22:553–558.
2008.
|
|
21
|
Rucinski M, Ziolkowska A, Tyczewska M and
Malendowicz LK: Expression of prepro-ghrelin and related receptor
genes in the rat adrenal gland and evidences that ghrelin exerts a
potent stimulating effect on corticosterone secretion by cultured
rat adrenocortical cells. Peptides. 30:1448–1455. 2009. View Article : Google Scholar
|
|
22
|
Gleichmann M, Gillen C, Czardybon M, et
al: Cloning and characterization of SDF-1gamma, a novel SDF-1
chemokine transcript with developmentally regulated expression in
the nervous system. Eur J Neurosci. 12:1857–1866. 2000. View Article : Google Scholar
|
|
23
|
De La Luz Sierra M, Yang F, Narazaki M, et
al: Differential processing of stromal-derived factor-1alpha and
stromal-derived factor-1beta explains functional diversity. Blood.
103:2452–2459. 2004.PubMed/NCBI
|
|
24
|
Yu L, Cecil J, Peng SB, Schrementi J, et
al: Identification and expression of novel isoforms of human
stromal cell-derived factor 1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Janowski M: Functional diversity of SDF-1
splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nowak-Markwitz E, Puła B, Szajnik M,
Dziegiel P, Piotrowska A, Zabel M and Spaczyński M: Expression of
survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer. Ginekol
Pol. 81:674–677. 2010.(In Polish).
|
|
27
|
Davis DA, Singer KE, De La Luz Sierra M,
et al: Identification of carboxypeptidase N as an enzyme
responsible for C-terminal cleavage of stromal cell-derived
factor-1alpha in the circulation. Blood. 105:4561–4568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kryczek I, Lange A, Mottram P, et al:
CXCL12 and vascular endothelial growth factor synergistically
induce neoangiogenesis in human ovarian cancers. Cancer Res.
65:465–472. 2005.
|
|
29
|
Oberlin E, Amara A, Bachelerie F, et al:
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
infection by T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bleul CC, Farzan M, Choe H, Parolin C,
Clark-Lewis I, Sodroski J and Springer TA: The lymphocyte
chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1
entry. Nature. 382:829–833. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
D’Apuzzo M, Rolink A, Loetscher M, et al:
The chemokine SDF-1, stromal cell-derived factor 1, attracts early
stage B cell precursors via the chemokine receptor CXCR4. Eur J
Immunol. 27:1788–1793. 1997.PubMed/NCBI
|
|
32
|
Fulton AM: The chemokine receptors CXCR4
and CXCR3 in cancer. Curr Oncol Rep. 11:125–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kucia M, Reca R, Miekus K, et al:
Trafficking of normal stem cells and metastasis of cancer stem
cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4
axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar
|
|
34
|
Sun X, Cheng G, Hao M, et al:
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer
Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Cai J, Han F, et al: Silencing of
CXCR4 blocks progression of ovarian cancer and depresses canonical
Wnt signaling pathway. Int J Gynecol Cancer. 21:981–987. 2011.
View Article : Google Scholar
|
|
36
|
Maksym RB, Tarnowski M, Grymula K, et al:
The role of stromal-derived factor-1 - CXCR7 axis in development
and cancer. Eur J Pharmacol. 625:31–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Potter SM, Dwyer RM, Curran CE, Hennessy
E, Harrington KA, Griffin DG and Kerin MJ: Systemic chemokine
levels in breast cancer patients and their relationship with
circulating menstrual hormones. Breast Cancer Res Treat.
115:279–287. 2009. View Article : Google Scholar
|
|
38
|
Tsai HT, Tee YT, Hsieh YH, et al: Elevated
plasma stromal cell-derived factor 1 protein and its gene
polymorphism in patients with pelvic inflammatory disease. Reprod
Sci. 16:610–617. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hansen IB, Ellingsen T, Hornung N, Poulsen
JH, Lottenburger T and Stengaard-Pedersen K: Plasma level of
CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is
independent of disease activity and methotrexate treatment. J
Rheumatol. 33:1754–1759. 2006.
|
|
40
|
Kim HK, Kim JE, Chung J, Lee DS, Han KS,
Park S and Cho HI: Plasma level of stromal derived factor-1 (SDF-1)
is increased in disseminated intravascular coagulation patients who
have poor outcomes: in vitro effect of SDF-1 on coagulopathy.
Thromb Res. 120:559–566. 2007. View Article : Google Scholar
|
|
41
|
Robak E, Kulczycka L, Sysa-Jedrzejowska A,
Wierzbowska A and Robak T: Circulating proangiogenic molecules
PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus
erythematosus. Eur Cytokine Netw. 18:181–187. 2007.
|
|
42
|
Huang R, Lin Y, Flowers L, et al:
Molecular profiling of circulating cytokine levels in human ovarian
cancer patients. Cancer Genomics Proteomics. 1:23–32. 2004.
|
|
43
|
Popple A, Durrant LG, Spendlove I, Rolland
P, Scott IV, Deen S and Ramage JM: The chemokine, CXCL12, is an
independent predictor of poor survival in ovarian cancer. Br J
Cancer. 106:1306–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Machelon V, Gaudin F, Camilleri-Broët S,
et al: CXCL12 expression by healthy and malignant ovarian
epithelial cells. BMC Cancer. 11:972011. View Article : Google Scholar : PubMed/NCBI
|
